CRO vs CDMO vs CMO: Who Does What Across a Drug's Lifecycle

The short answer: a CRO (Contract Research Organization) runs the research and clinical work — studies, trials, data — but does not manufacture your drug. A CMO (Contract Manufacturing Organization) manufactures to a process you have already developed and validated; it sells capacity. A CDMO (Contract Development and Manufacturing Organization) sits between and across the last two — it can develop the manufacturing process and then make the product. In one line: CRO = research, CMO = manufacturing, CDMO = development + manufacturing.

---

These three acronyms get used interchangeably, and getting them wrong wastes time and budget — you cannot ask a CRO to make your commercial supply, and you should not pay CDMO development rates for pure manufacturing capacity. This guide separates them cleanly, then shows how they hand off to each other across a program.

What a CRO does

A CRO provides outsourced research and development services — it is the knowledge and evidence layer, not the product layer. Typical scope:

• Preclinical work: toxicology, pharmacology, bioanalysis.
• Clinical trials: study design, site management, monitoring, patient recruitment across clinical phases.
• Data management, biostatistics, and regulatory/medical writing.

A CRO helps you prove a drug is safe and effective. It does not produce the doses you will sell. The two are so distinct that many sponsors run a CRO and a manufacturing partner in parallel throughout development.

What a CMO does

A CMO manufactures a drug substance or drug product to a process that already exists and is validated. The defining feature is that the process, formulation, and analytical methods are handed to the CMO — it supplies GMP-compliant capacity, equipment, and people to execute them, not the development behind them.

CMOs are often engaged for a single step — sterile fill-finish, packaging, or a specific unit operation — and a clean technology transfer is what makes or breaks the engagement.

What a CDMO does

A CDMO combines development and manufacturing. It can take a molecule and a target product profile and deliver process development, formulation, analytical method development, scale-up, and then clinical and commercial manufacturing — end to end, under one roof. Every CDMO can act as a CMO; the "D" (development) is the difference. For the two-way distinction in depth, see CDMO vs CMO.

Side by side

	CRO	CMO	CDMO
Core role	Research & clinical services	Manufacturing capacity	Development + manufacturing
Delivers	Data & evidence	Finished doses (to your process)	Process and finished doses
You bring	The molecule & study questions	A validated process	The molecule (and a target profile)
Typical stage	Preclinical → clinical	Late clinical → commercial	Early development → commercial
Makes your drug?	No	Yes	Yes

(You may also see CDO — a development-only organisation, effectively a CDMO without the manufacturing.)

How they work together across a program

For most sponsors this is not an either/or — it is a relay:

1. Discovery → preclinical: a CRO runs the safety and pharmacology studies while early material is made in small quantities.
2. Early development: a CDMO develops a scalable, GMP manufacturing process and supplies clinical-trial material — while the CRO runs the trials that consume it.
3. Late clinical → launch: the CDMO scales up and validates the commercial process; some sponsors then transfer the validated process to a lower-cost CMO for routine commercial supply, or dual-source it.

The practical implication: the label matters less than capability and regulatory record. A "CMO" that has quietly added development services is a CDMO in all but name; a CDMO with an open Warning Letter at the site that would make your product is a risk whatever it calls itself.

How to choose between them

• Need evidence, not doses? That is a CRO engagement.
• Have a finished, validated process and just need it made? That is a CMO — faster and cheaper than paying for development you do not need.
• Need the process built and then manufactured? That is a CDMO, and fewer technology transfers mean less risk than stitching together specialists.

Whichever type you are shortlisting, screen candidates on capability fit, capacity, GMP status, and FDA compliance history before you run an RFI. PharmaTek's supplier directory links recalls, Warning Letters, and Form 483 observations to each company profile so those risks surface before you engage — read our CDMO selection checklist for the full process.

Frequently asked questions

What is the difference between a CRO, a CMO, and a CDMO? A CRO provides research and clinical-trial services but does not manufacture your drug. A CMO manufactures to a process you have already developed and validated. A CDMO both develops the manufacturing process and manufactures the product. In short: CRO = research, CMO = manufacturing, CDMO = development plus manufacturing.

Is a CDMO the same as a CMO? No. A CMO provides manufacturing capacity for an existing, validated process. A CDMO also develops that process — formulation, analytical methods, scale-up — before manufacturing. Every CDMO can act as a CMO, but not every CMO offers development, which is why many CMOs that added development services now brand themselves as CDMOs.

Does a CRO manufacture drugs? No. A CRO delivers research, clinical-trial, and data services that prove a drug is safe and effective. Producing the commercial doses is the role of a CMO or CDMO. Sponsors typically run a CRO and a manufacturing partner in parallel.

Do I need a CRO and a CDMO at the same time? Often yes. During clinical development a CDMO makes the trial material while a CRO runs the trials that use it. They cover different layers — evidence versus product — so they usually run in parallel rather than replacing each other.

Which is cheaper, a CMO or a CDMO? For pure manufacturing of an already-developed process, a CMO is usually cheaper because you are not paying for development. A CDMO costs more up front but can be more efficient overall when you need the process developed too, because it avoids extra technology transfers between separate specialists.

---

Comparing partners across all three types? Explore the supplier directory or book a demo to shortlist and screen candidates against live FDA compliance data.